Literature DB >> 16793320

The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment.

I-Sheng Lin1, Ruey-Meei Wu, Guey-Jen Lee-Chen, Din-E Shan, Katrina Gwinn-Hardy.   

Abstract

Spinocerebellar ataxia (SCA) 17 is a dominant neurodegenerative disorder characterized by ataxia, cognitive decline, dystonia, and parkinsonism. The disease is caused by unstable cytosine-adenine-guanine (CAG) trinucleotide expansion mutation coding for polyglutamine tracts in the TATA box-binding protein (TBP), a general transcription initiation factor. Herein, we report a SCA17 case with a phenotype not previously reported, which consisted of progressive ataxia, autonomic dysfunction, parkinsonism, supranuclear palsy and cognitive impairment. Cerebrospinal fluid study and 18F-dopa PET scanning demonstrated dopamine deficiency and nigrostrital degeneration. This case expands the current phenotype associated with SCA17. SCA17 should be considered in the differential diagnosis of cases resembling multiple system atrophy, especially those with atypical features.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793320     DOI: 10.1016/j.parkreldis.2006.04.009

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  21 in total

Review 1.  Vertical supranuclear gaze palsy in Niemann-Pick type C disease.

Authors:  Ettore Salsano; Chizoba Umeh; Alessandra Rufa; Davide Pareyson; David S Zee
Journal:  Neurol Sci       Date:  2012-07-19       Impact factor: 3.307

Review 2.  Neuroimaging in Dementia.

Authors:  Adam M Staffaroni; Fanny M Elahi; Dana McDermott; Kacey Marton; Elissaios Karageorgiou; Simone Sacco; Matteo Paoletti; Eduardo Caverzasi; Christopher P Hess; Howard J Rosen; Michael D Geschwind
Journal:  Semin Neurol       Date:  2017-12-05       Impact factor: 3.420

3.  Psychotic-affective symptoms and multiple system atrophy expand phenotypes of spinocerebellar ataxia type 2.

Authors:  Kai-Hsiang Chen; Chin-Hsien Lin; Ruey-Meei Wu
Journal:  BMJ Case Rep       Date:  2012-03-20

Review 4.  Exploring the Potential of Small Molecule-Based Therapeutic Approaches for Targeting Trinucleotide Repeat Disorders.

Authors:  Arun Kumar Verma; Eshan Khan; Sonali R Bhagwat; Amit Kumar
Journal:  Mol Neurobiol       Date:  2019-08-09       Impact factor: 5.590

5.  Structural changes associated with progression of motor deficits in spinocerebellar ataxia 17.

Authors:  Kathrin Reetz; Rebekka Lencer; Johannes M Hagenah; Christian Gaser; Vera Tadic; Uwe Walter; Alexander Wolters; Susanne Steinlechner; Christine Zühlke; Katja Brockmann; Christine Klein; Arndt Rolfs; Ferdinand Binkofski
Journal:  Cerebellum       Date:  2010-06       Impact factor: 3.847

6.  Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4).

Authors:  Giovanni Stevanin; Alexis Brice
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

Review 7.  Neuroimaging in dementia.

Authors:  Paolo Vitali; Raffaella Migliaccio; Federica Agosta; Howard J Rosen; Michael D Geschwind
Journal:  Semin Neurol       Date:  2008-10-08       Impact factor: 3.420

8.  Spinocerebellar ataxia type 17 (SCA17): oculomotor phenotype and clinical characterization of 15 Italian patients.

Authors:  Caterina Mariotti; Dario Alpini; Roberto Fancellu; Paola Soliveri; Marina Grisoli; Sabrina Ravaglia; Carlo Lovati; Vincenza Fetoni; Giorgio Giaccone; Alessia Castucci; Franco Taroni; Cinzia Gellera; Stefano Di Donato
Journal:  J Neurol       Date:  2007-10-15       Impact factor: 4.849

Review 9.  Multiple system atrophy: the application of genetics in understanding etiology.

Authors:  Monica Federoff; Lucia V Schottlaender; Henry Houlden; Andrew Singleton
Journal:  Clin Auton Res       Date:  2015-02-17       Impact factor: 4.435

10.  Severe and rapidly progressing cognitive phenotype in a SCA17-family with only marginally expanded CAG/CAA repeats in the TATA-box binding protein gene: a case report.

Authors:  Troels Tolstrup Nielsen; Skirmante Mardosiene; Annemette Løkkegaard; Jette Stokholm; Susanne Ehrenfels; Sara Bech; Lars Friberg; Jens Kellberg Nielsen; Jørgen E Nielsen
Journal:  BMC Neurol       Date:  2012-08-13       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.